Boardroom Alpha
Boardroom Alpha
KYNB · Additional Proxy Materials (DEFA14A) · Filed April 27, 2026

Kyntra Bio Inc — Additional Proxy Materials (DEFA14A)

Form
DEFA14A
Filed
April 27, 2026
Ticker
KYNB
Accession
0001193125-26-182071
Boardroom Alpha · Filing insights

Kyntra Bio's board urges votes for director election, say-on-pay, and PwC audit ratification.

About Kyntra Bio Inc
Market cap
$28M
1Y TSR
+5.3%
3Y TSR
−72.8%
Board grade
C-
Sector
Healthcare
CEO
Thane Wettig
Last annual meeting: Jun 12, 2026 · View full Kyntra Bio Inc profile →
DEFA14A

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

SCHEDULE 14A

Proxy Statement Pursuant to Section 14(a) of the

Securities Exchange Act of 1934

(Amendment No. )

 

 

Filed by the Registrant

Filed by a Party other than the Registrant

Check the appropriate box:

Preliminary Proxy Statement

Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

Definitive Proxy Statement

Definitive Additional Materials

Soliciting Material under §240.14a-12

Kyntra Bio, Inc.

(Name of Registrant as Specified In Its Charter)

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check the appropriate box):

No fee required.

Fee paid previously with preliminary materials.

Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.

 


 

img103820090_0.jpg

Your Vote Counts! KYNTRA BIO, INC. 2026 Annual Meeting Vote by June 11, 2026 11:59 PM ET [Alt text was not generated.] KYNTRA BIO, INC. 350 BAY ST, STE 100 # 6009 SAN FRANCISCO, CA 94133 V95441-P46761 You invested in KYNTRA BIO, INC. and it’s time to vote! You have the right to vote on proposals being presented at the Annual Meeting. This is an important notice regarding the availability of proxy materials for the stockholder meeting to be held on June 12, 2026. Get informed before you vote View the Notice and Proxy Statement and Annual Report on Form 10-K online OR you can receive a free paper or email copy of the material(s) by requesting prior to May 29, 2026. If you would like to request a copy of the material(s) for this and/or future stockholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to sendmaterial@proxyvote.com. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy. For complete information and to vote, visit www.ProxyVote.com Control # Smartphone users Point your camera here and vote without entering a control number Vote Virtually at the Meeting* June 12, 2026 8:00 AM Pacific Time Virtually at: www.virtualshareholdermeeting.com/KYNB2026 *Please check the meeting materials for any special requirements for meeting attendance.


 

img103820090_1.jpg

Vote at www.ProxyVote.com THIS IS NOT A VOTABLE BALLOT This is an overview of the proposals being presented at the upcoming stockholder meeting. Please follow the instructions on the reverse side to vote these important matters. Board Recommends Voting Items 1. To elect a Class III director to hold office until the 2029 Annual Meeting of Stockholders. Nominee: 1a. Michael Kauffman, M.D., Ph.D. For 2. To approve, on an advisory basis, the compensation of the Company’s named executive officers. For 3. To ratify the selection, by the Audit Committee of the Board, of PricewaterhouseCoopers LLP as the independent registered public accounting firm of the Company for the year ending December 31, 2026. For 4. To conduct any other business properly brought before the meeting. Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click “Delivery Settings”. V95442-P46761


From this filing to the vote

Forecast every director vote the day the proxy files.

Meeting Forecast scores each director up for re-election + every contested situation, rebuilt daily across 6,000+ U.S. public companies. The same model that called the LULU contested proxy lives on every meeting you see here.

Independent — issuer-pays-free, ideology-free, U.S.-owned.

More filings

Other filings from Kyntra Bio Inc (KYNB)

Reference

Frequently asked questions

When did Kyntra Bio Inc file this DEFA14A?
Kyntra Bio Inc (KYNB) filed this Additional Proxy Materials (DEFA14A) with the SEC on April 27, 2026. The accession number assigned by EDGAR is 0001193125-26-182071.
What does a DEFA14A disclose?
DEFA14A is additional definitive proxy soliciting material filed in connection with a shareholder meeting — supplemental letters, slides, or amendments issued after the main proxy statement.
What is the key takeaway from this filing?
Kyntra Bio's board urges votes for director election, say-on-pay, and PwC audit ratification. This is Boardroom Alpha's one-line summary of the additional proxy materials; see the full filing text above for the formal disclosure.
Where can I find Kyntra Bio Inc's prior proxy statements on EDGAR?
The SEC EDGAR browser lists every DEFA14A Kyntra Bio Inc has filed under CIK 921299, sortable by date. Use the "View on SEC EDGAR" link in the page header, or browse directly via https://www.sec.gov/cgi-bin/browse-edgar.
Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer